FIRST-LINE IMMUNOCHEMOTHERAPY FOR FOLLICULAR LYMPHOMA PATIENTS- SINGLE CENTER EXPERIENCE
Trajkova S. First-line immunochemotherapy
Abstract
Introduction: First line therapy of follicular lymphoma (FL) patients is based on anti CD20 immmunotherapy combined with chemotherapy with or without anthracycline. Data from studies presented a superior progression-free survival advantage in favor of Obinutuzumab (O) vs. Rituximab (R)-based immunochemotherapies as first-line therapy in FL patients. Nevertheless the studies presented more adverse events at the same treatment group.
Aim of the study: Evaluation of response from first line therapy and adverse events of first-line rituximab vs. obinutuzumab-based immunochemotherapies.
Materials and methods: This is a single center retrospective study presented with 143 adult FL patients diagnosed ad treted at University clinic for hematology, Skopje, N.Macedonia in a period of five years (2018-2022). The response from first line therapy and adverse events profile of first-line rituximab vs. obinutuzumab-based immunochemotherapies were compared.
Results: A total of 143 patients were included in the analysis, 44% were treated with rituximab and 54,5% with obinutuzumab-based immunochemotherapy.Most of the patients 41,9% have advanced disease (Stage 4), FLIPI 3 (38,4%) and FLIPI 2 and 4 (21,6%). Most of the patiens had ECOG 1 (41%). Overall 33.5% of patients experienced infections and 39,1% had COVID infection. Patients treated with O v.s R have high rate of infection (44,8% and 13,3%) (p=0,005), febrile neutropenia was found at 46,1% (O) and 34% (R) treated with G-CSF. At the end of the study complete response was achieved at 69,2%, partal response at 4,1%, 20% of patients died and 11% died from COVID infection (25% of patients previously treated with R and 75% with O (p=0,001)).
Conclusion: In this retrospective study of first-line treated FL patients comparing R- to O-based therapy, we did observe difference in adverese events profile in two treatment groups in favor of O treatment group.
Keywords: FL, Obinutuzumab; Rituximab, adverese events, infection.
References
Brice P, Lemonnier F, Martin A, Casasnovas O, Pedersen LM, Dorvaux V, Simpson D, Leppa S,
Gabarre J, da Silva MG, Glaisner S, Ysebaert L, Vekhoff A, Intragumtornchai T, Le Gouill S, Lister
A, Estell JA, Milone G, Sonet A, Farhi J, Zeuner H, Tilly H, Salles G. Sustained Progression-Free
Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term
Results of the PRIMA Study. J Clin Oncol. 2019 Nov 1;37(31):2815-2824. doi:
10.1200/JCO.19.01073. Epub 2019 Jul 24. PMID: 31339826; PMCID: PMC6823890.
2. Townsend W, Hiddemann W, Buske C, Cartron G, Cunningham D, Dyer MJS, Gribben JG, Phillips
EH, Dreyling M, Seymour JF, Grigg A, Trotman J, Lin TY, Hong XN, Kingbiel D, Nielsen TG,
Knapp A, Herold M, Marcus R. Obinutuzumab Versus Rituximab Immunochemotherapy in
Previously Untreated iNHL: Final Results From the GALLIUM Study. Hemasphere. 2023 Jun
30;7(7):e919. doi: 10.1097/HS9.0000000000000919. PMID: 37404773; PMCID: PMC10317485.
3. Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben
J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N,
Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M,
Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell
S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal
A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ,
Seshan VE. International Working Group consensus response evaluation criteria in lymphoma
(RECIL 2017). Ann Oncol. 2017 Jul 1;28(7):1436-1447. doi: 10.1093/annonc/mdx097. PMID:
28379322; PMCID: PMC5834038.
